AR118557A1 - IRON CHELANTS DERIVED FROM BENZOIC ACID 4- (2,4-BIS (2-HYDROXYPHENIL) -1H-IMIDAZOL-1-IL) - Google Patents

IRON CHELANTS DERIVED FROM BENZOIC ACID 4- (2,4-BIS (2-HYDROXYPHENIL) -1H-IMIDAZOL-1-IL)

Info

Publication number
AR118557A1
AR118557A1 ARP200100910A ARP200100910A AR118557A1 AR 118557 A1 AR118557 A1 AR 118557A1 AR P200100910 A ARP200100910 A AR P200100910A AR P200100910 A ARP200100910 A AR P200100910A AR 118557 A1 AR118557 A1 AR 118557A1
Authority
AR
Argentina
Prior art keywords
substituents
alkyl
alkoxy
carry
group
Prior art date
Application number
ARP200100910A
Other languages
Spanish (es)
Inventor
Klaus Umland
- Nyffenegger Naja Daniel
Vania Manolova
Aris Kalogerakis
Franz Drrenberger
Michael Burgert
Wilm Buhr
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of AR118557A1 publication Critical patent/AR118557A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B57/00—Other synthetic dyes of known constitution
    • C09B57/10—Metal complexes of organic compounds not being dyes in uncomplexed form

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Compuestos de acuerdo con la fórmula (1) en donde el grupo -COR¹ representa un grupo -(C=O)-R¹, en donde R¹ se selecciona entre el grupo que consiste en -OH, alcoxi C₁₋₄, halógenoalquilo C₁₋₄ que tiene de 1 a 3 átomos de halógeno, halógenoalcoxi C₁₋₄ que tiene de 1 a 3 átomos de halógeno, y un grupo desprotonado -O ¹⁵; o una forma salina del mismo; R² representa uno o más sustituyentes seleccionados independientemente entre el grupo que consiste en hidrógeno, halógeno, -OH, alquilo C₁₋₆ lineal o ramificado que puede llevar 1, 2 ó 3 sustituyentes, cicloalquilo C₃₋₆ que puede llevar 1, 2 ó 3 sustituyentes, y alcoxi C₁₋₆ que puede llevar 1, 2 ó 3 sustituyentes, en donde los sustituyentes de alquilo, cicloalquilo y alcoxi pueden ser iguales o diferentes y pueden seleccionarse independientemente entre el grupo que consiste en halógeno, alquilo C₁₋₃, alcoxi C₁₋₃, en donde el sustituyente alquilo y alcoxi cada uno puede llevar 1, 2 ó 3 sustituyentes adicionales seleccionados independientemente entre halógeno, alquilo C₁₋₃ y alcoxi C₁₋₃; R³ se selecciona entre el grupo que consiste en hidrógeno, alquilo C₁₋₄ lineal o ramificado que puede llevar 1, 2 ó 3 sustituyentes, y cicloalquilo C₃₋₆ que puede llevar 1, 2 ó 3 sustituyentes, en donde los sustituyentes de alquilo y cicloalquilo pueden ser iguales o diferentes y pueden seleccionarse entre el grupo que consiste en halógeno, alquilo C₁₋₃ y alcoxi C₁₋₃, en donde el sustituyente alquilo y alcoxi cada uno puede llevar 1, 2 ó 3 sustituyentes adicionales seleccionados independientemente entre halógeno, alquilo C₁₋₃ y alcoxi C₁₋₃; R⁴ y R⁵ cada uno representan, uno o más sustituyentes seleccionados independientemente entre el grupo que consiste en hidrógeno, halógeno, -OH, alquilo C₁₋₆ lineal o ramificado que puede llevar 1, 2 ó 3 sustituyentes, cicloalquilo C₃₋₆ que puede llevar 1, 2 ó 3 sustituyentes, y alcoxi C₁₋₆ que puede llevar 1, 2 ó 3 sustituyentes, en donde los sustituyentes de alquilo, cicloalquilo y alcoxi pueden ser iguales o diferentes y pueden seleccionarse independientemente entre el grupo que consiste en halógeno, ciano, alquilo C₁₋₃ y alcoxi C₁₋₃, en donde el sustituyente alquilo y alcoxi cada uno puede llevar 1, 2 ó 3 sustituyentes adicionales seleccionados independientemente entre alquilo C₁₋₃ y alcoxi C₁₋₃; R⁶ y R⁶’ cada uno representa uno o más sustituyentes seleccionados independientemente entre el grupo que consiste en hidrógeno, una carga negativa ¹⁵; o una forma salina de la misma; y sales farmacéuticamente aceptables de los mismos.Claim 1: Compounds according to formula (1) wherein the group -COR¹ represents a group - (C = O) -R¹, wherein R¹ is selected from the group consisting of -OH, C₁₋₄ alkoxy, haloalkyl C₁₋₄ having 1 to 3 halogen atoms, C₁₋₄ halogenoalkoxy having 1 to 3 halogen atoms, and a deprotonated group -O¹⁵; or a salt form thereof; R² represents one or more substituents independently selected from the group consisting of hydrogen, halogen, -OH, C₁₋₆ linear or branched alkyl which may carry 1, 2 or 3 substituents, C₃₋₆ cycloalkyl which may carry 1, 2 or 3 substituents, and C₁₋₆ alkoxy which may carry 1, 2 or 3 substituents, wherein the alkyl, cycloalkyl and alkoxy substituents may be the same or different and may be independently selected from the group consisting of halogen, C₁₋₃ alkyl, alkoxy C₁₋₃, wherein the alkyl and alkoxy substituent may each carry 1, 2, or 3 additional substituents independently selected from halogen, C₁₋₃ alkyl, and C₁₋₃ alkoxy; R³ is selected from the group consisting of hydrogen, C₁₋₄ linear or branched alkyl which may carry 1, 2 or 3 substituents, and C₃₋₆ cycloalkyl which may carry 1, 2 or 3 substituents, wherein the alkyl substituents and Cycloalkyl may be the same or different and may be selected from the group consisting of halogen, C₁₋₃ alkyl, and C₁₋₃ alkoxy, wherein the alkyl and alkoxy substituent may each carry 1, 2, or 3 additional substituents independently selected from halogen, C₁₋₃ alkyl and C₁₋₃ alkoxy; R⁴ and R⁵ each represent, one or more substituents independently selected from the group consisting of hydrogen, halogen, -OH, C₁₋₆ linear or branched alkyl which may carry 1, 2 or 3 substituents, C₃₋₆ cycloalkyl which may carry 1, 2 or 3 substituents, and C₁₋₆ alkoxy which may carry 1, 2 or 3 substituents, wherein the alkyl, cycloalkyl and alkoxy substituents may be the same or different and may be independently selected from the group consisting of halogen, cyano , C₁₋₃ alkyl and C₁₋₃ alkoxy, wherein the alkyl and alkoxy substituent each may carry 1, 2 or 3 additional substituents independently selected from C₁₋₃ alkyl and C₁₋₃ alkoxy; R⁶ and R⁶ 'each represent one or more substituents independently selected from the group consisting of hydrogen, a negative charge ¹⁵; or a salt form thereof; and pharmaceutically acceptable salts thereof.

ARP200100910A 2019-04-01 2020-04-01 IRON CHELANTS DERIVED FROM BENZOIC ACID 4- (2,4-BIS (2-HYDROXYPHENIL) -1H-IMIDAZOL-1-IL) AR118557A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19166496 2019-04-01

Publications (1)

Publication Number Publication Date
AR118557A1 true AR118557A1 (en) 2021-10-20

Family

ID=66049043

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100910A AR118557A1 (en) 2019-04-01 2020-04-01 IRON CHELANTS DERIVED FROM BENZOIC ACID 4- (2,4-BIS (2-HYDROXYPHENIL) -1H-IMIDAZOL-1-IL)

Country Status (3)

Country Link
AR (1) AR118557A1 (en)
TW (1) TW202102478A (en)
WO (1) WO2020201305A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1010291B (en) * 2021-03-02 2022-08-30 Demo Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακων, Nutritional supplement for use in reducing and/or preventing iron overload complications
CN114276305B (en) * 2021-12-28 2023-11-17 中山大学 Trisubstituted phenyl-1, 2, 4-triazole derivative, preparation method thereof and application thereof in treatment of neuronal injury
US11976046B1 (en) 2023-10-25 2024-05-07 King Faisal University 4-(4,5-bis(4-bromophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320802A1 (en) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenyl-substituted imidazoles, their use as pharmaceutical agents and pharmaceutical compositions containing them
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
US5922761A (en) 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
AR009655A1 (en) 1996-12-10 2000-04-26 Novartis Ag A PARENTERALLY INJECTABLE COMPOSITION, A METHOD FOR ITS PREPARATION, METHODS FOR THE TREATMENT OF DISEASES, A CRYSTAL MODIFICATION OF 1-DECANSULFONATE OF DESPHERRIOXAMINE, ITS USE, A PROCESS FOR THE PRODUCTION OF SUCH CRYSTAL MODIFICATION AND A PREPARATION FOR PHARMACEUTICAL PREPARATION
EP1074254A3 (en) 1999-07-20 2002-09-11 MEDIS S.r.l. Medical Infusion Systems Use of plant polyphenols with vitamines for treating iron overload
EP1072265A1 (en) 1999-07-20 2001-01-31 MEDIS S.r.l. Medical Infusion Systems Use of plant polyphenols for treating iron overload
US20030109548A1 (en) 2001-11-09 2003-06-12 Royt Paulette W. Compositions and methods of treating iron excess
DE10356409B4 (en) 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh New drug oxacheline and derivatives
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
CL2008000666A1 (en) 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc COMPOUNDS DERIVED FROM SUBSTITUTED TRICYCLES, INHIBITORS OF THE DIVALENT-1 METAL TRANSPORTER; AND USE TO TREAT AN ILLNESS ASSOCIATED WITH AN IRON DISORDER.
AR065785A1 (en) 2007-03-19 2009-07-01 Xenon Pharmaceuticals Inc BIARETO AND BIHETEROARILE COMPOUNDS OF UTILITY IN THE TREATMENT OF IRON DISORDERS
EP2128171A1 (en) 2007-03-20 2009-12-02 Meiji Seika Kaisha Ltd. Agent for prevention or treatment of iron overload
CL2008000793A1 (en) 2007-03-23 2008-05-30 Xenon Pharmaceuticals Inc COMPOUNDS DERIVED FROM DIHYDROINDAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT AN IRON DISORDER.
US20100240713A1 (en) 2007-06-05 2010-09-23 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
CN104011066A (en) 2011-12-09 2014-08-27 加利福尼亚大学董事会 Modified mini-hepcidin peptides and methods of using thereof
AU2013235491A1 (en) 2012-03-22 2014-09-11 Nanotherapeutics, Inc. Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
US20160243201A1 (en) 2013-11-05 2016-08-25 New York Blood Center, Inc. Methods and compositions for increasing hepcidin expession using modified iron binding/releasing transferrin
WO2015077655A1 (en) 2013-11-22 2015-05-28 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
EP3365339A1 (en) 2015-10-23 2018-08-29 Vifor (International) AG Novel ferroportin inhibitors
JOP20180036A1 (en) 2017-04-18 2019-01-30 Vifor Int Ag Novel ferroportin-inhibitor salts

Also Published As

Publication number Publication date
WO2020201305A1 (en) 2020-10-08
TW202102478A (en) 2021-01-16

Similar Documents

Publication Publication Date Title
AR118557A1 (en) IRON CHELANTS DERIVED FROM BENZOIC ACID 4- (2,4-BIS (2-HYDROXYPHENIL) -1H-IMIDAZOL-1-IL)
AR091519A1 (en) TANQUIRASA PIRROLOPIRAZONA INHIBITORS
AR101815A1 (en) COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
AR100033A1 (en) COMPOUNDS AND COMPOSITIONS TO INHIBIT THE ACTIVITY OF SHP2
AR089671A1 (en) 1,4-DIHIDROPIRIMIDINAS 4,4-DISUSTITUIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
AR090867A1 (en) PESTICIDED COMPOUNDS AND COMPOSITIONS AND RELATED PROCESSES
AR096684A1 (en) COMPOUNDS TO TREAT SPINAL MUSCLE ATROPHY
AR088692A1 (en) DERIVATIVES OF 2- (1,2,3-TRIAZOL-2-IL) BENZAMINE AND 3- (1,2,3-TRIAZOL-2-IL) PICOLINAMIDE
AR052866A1 (en) SUBSTITUTED MONOCICLIC PHENYL-METANONES
AR108778A1 (en) ANTIBACTERIAL COMPOUNDS
AR100712A1 (en) PIRAZOL COMPOUNDS AS BLOCKERS OF TYPE T CALCIUM CHANNELS
EA200602058A1 (en) DERIVATIVES OF ADAMANTILPYRROLIDIN-2-IT AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROID-DEGYDROGENASE
ES2626801T3 (en) Triazolopyridine compounds as pde10a inhibitors
AR109711A1 (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
AR125026A1 (en) CARDIAC SARCOMERE INHIBITORS
AR106604A1 (en) CRYPTOFICINE COMPOUNDS AND CONJUGATED PRODUCTS, THEIR PREPARATION AND THERAPEUTIC USE
AR102258A1 (en) QUINOLINE AND QUINAZOLINE COMPOUNDS
AR101222A1 (en) DERIVATIVES OF PIRIDONA
AR114374A1 (en) HERBICIDE COMPOUNDS
AR104533A1 (en) DERIVATIVES OF CARBOXYLIC CYCLOPROPAN ACID AND ITS USES AS LEUCOTRIEN CH SINTASA INHIBITORS
AR088021A1 (en) DERIVATIVES OF OXADIAZOLS AND PIRIDAZINES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
AR122336A1 (en) HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE
AR107398A1 (en) 2-OXINDOL COMPOUNDS
AR117929A1 (en) 1,2,4-TRIAZIN-3 (2H) -ONE COMPOUNDS
AR092547A1 (en) ISOXAZOLIDINE DERIVATIVES

Legal Events

Date Code Title Description
FB Suspension of granting procedure